Dupixent® (dupilumab) data presented at ats reinforce impact of targeting key type 2 inflammation drivers to improve outcomes for chronic respiratory diseases

24 abstracts, including 1 oral presentation and 4 late-breaking posters on dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (copd) and asthma
REGN Ratings Summary
REGN Quant Ranking